Do aML-loaded DC generate Th1-type cellular immune responses in vitro?
These data support further research into the use of this strategy as an alternative approach to leukemia-derived DC vaccination.
For very low-birth-weight neonates (<2.0 kg) with congenital heart defects, imposed delays in intervention neither compromise nor improve survival. Other factors instead appear to account for survival differences, including lesion type, associated noncardiac congenital defects, and antenatal diagnosis.